“Primary Care” division to become “Consumer Healthcare”

Strong operating performance exceeds guidance with Group sales up 11.8% driven by Specialty Care and Core Operating Margin improvement despite Cabometyx launch investments

Acquisition of Onivyde and new Primary Care products expected to close during the first half of 2017

• Acceleration of Group sales growth at 12.2%¹ in the third quarter resulting in 10.5%¹ sales growth for the first 9 months driven by Specialty Care
• Guidance 2016 raised

• Group sales up 9.7%¹ driven by Specialty Care growth of 14.3%¹ , notably due to strong performance of Somatuline^®
• Core Operating Income up 12.6% fueled by strong top-line growth
• Core diluted EPS of €1.74, up 16.0%

• Group sales up 4.7%¹
  • Specialty care sales up 9.7%¹, driven by the accelerated growth of Somatuline^® in neuroendocrine tumors
  • Primary care sales down 11.0%¹ , impacted by the slowdown in international markets
• 2016 financial objectives confirmed

• Operating performance in line with guidance, with Group sales up 10.4%1 and Core Operating Income up 23.8%
• Core diluted EPS of €2.78, up 25.3%, and sound cash flow generation with closing cash of €214.0 million
• Proposal of a dividend of €0.85 per share